Format

Send to

Choose Destination
Curr Cancer Drug Targets. 2018 Apr 30. doi: 10.2174/1568009618666180430143055. [Epub ahead of print]

PRDM14: a potential target for cancer therapy.

Author information

1
Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044. China.

Abstract

PRDM14 belongs to PR domain-containing (PRDM) family. Although a precise understanding is focused on the function of PRDM14 maintains stemness and pluripotency in embryonic stem cells via epigenetic mechanisms, there are growing experimental evidences have been linked PRDM14 to human cancers. In adults, PRDM14 is low expression in human tissues. Aberrant PRDM14 expression is connected with various malignant histological types and solid cancers, where PRDM14 can act as a driver of oncogenic processes. Overexpression of RPDM14 enhanced cancer cells growth and reduced cancer cells sensitive to chemotherapeutic agents. Rather, reducing the expression of PRDM14 in cancer cells can enhance the therapeutic sensitivity of drugs to cancer cells, suggesting that aberrant PRDM14 may have a carcinogenic characteristic in tumor therapy and as a new molecular target. This review summarizes the structure and oncogenic properties of PRDM14 in different malignancies and suggests that PRDM14 may be a potential therapeutic molecular target for tumor treatment.

KEYWORDS:

PRDM family; PRDM14; cancer therapy; chemotherapeutic resistance; molecular therapeutic target; oncogene

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center